JNJ-64407564

· Janssen Pharmaceutical K.K.

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for JNJ-64407564, covering 2025-10-01 to 2025-10-01. Get the full timeline:

Most recent: Clinical Trial Update: A Study of JNJ-64407564 in Japanese Participants With Relapsed or Refractory Multiple Myeloma [Phase 1]